Application of the national institute on aging-alzheimer's association AD criteria to ADNI

Val Lowe, Patrick J. Peller, Stephen D. Weigand, Catalina Montoya Quintero, Nirubol Tosakulwong, Prashanthi D Vemuri, Matthew L. Senjem, Lennon Jordan, Clifford R Jr. Jack, David S Knopman, Ronald Carl Petersen

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective: Wedescribe the operationalization of theNational Institute on Aging-Alzheimer's Association (NIA-AA) workgroup diagnostic guidelines pertaining to Alzheimer disease (AD) dementia in a large multicenter group of subjects with AD dementia. Methods: Subjects with AD dementia from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with at least 1 amyloid biomarker (n = 211) were included in this report. Biomarker data from CSF Aβ42, amyloid PET, fluorodeoxyglucose-PET, and MRI were examined. The biomarker results were assessed on a per-patient basis and the subject categorization as defined in theNIA-AAworkgroup guidelines was determined. Results: When using a requirement that subjects have a positive amyloid biomarker and single neuronal injury marker having an AD pattern, 87% (48% for both neuronal injury biomarkers) of the subjects could be categorized as "high probability" for AD. Amyloid status of the combined Pittsburgh compound B-PET and CSF results showed an amyloid-negative rate of 10% in the AD group. In the ADNI AD group, 5 of 92 subjects fit the category "dementia unlikely due to AD" when at least one neuronal injury marker was negative. Conclusions: A large proportion of subjects with AD dementia in ADNI may be categorized more definitively as high-probability AD using the proposed biomarker scheme in the NIA-AA criteria. A minority of subjects may be excluded from the diagnosis of AD by using biomarkers in clinically categorized AD subjects. In a well-defined AD dementia population, significant biomarker inconsistency can be seen on a per-patient basis.

Original languageEnglish (US)
Pages (from-to)2130-2137
Number of pages8
JournalNeurology
Volume80
Issue number23
DOIs
StatePublished - Jun 4 2013

Fingerprint

National Institute on Aging (U.S.)
Neuroimaging
Alzheimer Disease
Biomarkers
Amyloid
Alzheimer
Alzheimer's Disease
Wounds and Injuries

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Application of the national institute on aging-alzheimer's association AD criteria to ADNI. / Lowe, Val; Peller, Patrick J.; Weigand, Stephen D.; Quintero, Catalina Montoya; Tosakulwong, Nirubol; Vemuri, Prashanthi D; Senjem, Matthew L.; Jordan, Lennon; Jack, Clifford R Jr.; Knopman, David S; Petersen, Ronald Carl.

In: Neurology, Vol. 80, No. 23, 04.06.2013, p. 2130-2137.

Research output: Contribution to journalArticle

Lowe, Val ; Peller, Patrick J. ; Weigand, Stephen D. ; Quintero, Catalina Montoya ; Tosakulwong, Nirubol ; Vemuri, Prashanthi D ; Senjem, Matthew L. ; Jordan, Lennon ; Jack, Clifford R Jr. ; Knopman, David S ; Petersen, Ronald Carl. / Application of the national institute on aging-alzheimer's association AD criteria to ADNI. In: Neurology. 2013 ; Vol. 80, No. 23. pp. 2130-2137.
@article{b05c3a57f0bd478b952f0613727e66f3,
title = "Application of the national institute on aging-alzheimer's association AD criteria to ADNI",
abstract = "Objective: Wedescribe the operationalization of theNational Institute on Aging-Alzheimer's Association (NIA-AA) workgroup diagnostic guidelines pertaining to Alzheimer disease (AD) dementia in a large multicenter group of subjects with AD dementia. Methods: Subjects with AD dementia from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with at least 1 amyloid biomarker (n = 211) were included in this report. Biomarker data from CSF Aβ42, amyloid PET, fluorodeoxyglucose-PET, and MRI were examined. The biomarker results were assessed on a per-patient basis and the subject categorization as defined in theNIA-AAworkgroup guidelines was determined. Results: When using a requirement that subjects have a positive amyloid biomarker and single neuronal injury marker having an AD pattern, 87{\%} (48{\%} for both neuronal injury biomarkers) of the subjects could be categorized as {"}high probability{"} for AD. Amyloid status of the combined Pittsburgh compound B-PET and CSF results showed an amyloid-negative rate of 10{\%} in the AD group. In the ADNI AD group, 5 of 92 subjects fit the category {"}dementia unlikely due to AD{"} when at least one neuronal injury marker was negative. Conclusions: A large proportion of subjects with AD dementia in ADNI may be categorized more definitively as high-probability AD using the proposed biomarker scheme in the NIA-AA criteria. A minority of subjects may be excluded from the diagnosis of AD by using biomarkers in clinically categorized AD subjects. In a well-defined AD dementia population, significant biomarker inconsistency can be seen on a per-patient basis.",
author = "Val Lowe and Peller, {Patrick J.} and Weigand, {Stephen D.} and Quintero, {Catalina Montoya} and Nirubol Tosakulwong and Vemuri, {Prashanthi D} and Senjem, {Matthew L.} and Lennon Jordan and Jack, {Clifford R Jr.} and Knopman, {David S} and Petersen, {Ronald Carl}",
year = "2013",
month = "6",
day = "4",
doi = "10.1212/WNL.0b013e318295d6cf",
language = "English (US)",
volume = "80",
pages = "2130--2137",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

TY - JOUR

T1 - Application of the national institute on aging-alzheimer's association AD criteria to ADNI

AU - Lowe, Val

AU - Peller, Patrick J.

AU - Weigand, Stephen D.

AU - Quintero, Catalina Montoya

AU - Tosakulwong, Nirubol

AU - Vemuri, Prashanthi D

AU - Senjem, Matthew L.

AU - Jordan, Lennon

AU - Jack, Clifford R Jr.

AU - Knopman, David S

AU - Petersen, Ronald Carl

PY - 2013/6/4

Y1 - 2013/6/4

N2 - Objective: Wedescribe the operationalization of theNational Institute on Aging-Alzheimer's Association (NIA-AA) workgroup diagnostic guidelines pertaining to Alzheimer disease (AD) dementia in a large multicenter group of subjects with AD dementia. Methods: Subjects with AD dementia from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with at least 1 amyloid biomarker (n = 211) were included in this report. Biomarker data from CSF Aβ42, amyloid PET, fluorodeoxyglucose-PET, and MRI were examined. The biomarker results were assessed on a per-patient basis and the subject categorization as defined in theNIA-AAworkgroup guidelines was determined. Results: When using a requirement that subjects have a positive amyloid biomarker and single neuronal injury marker having an AD pattern, 87% (48% for both neuronal injury biomarkers) of the subjects could be categorized as "high probability" for AD. Amyloid status of the combined Pittsburgh compound B-PET and CSF results showed an amyloid-negative rate of 10% in the AD group. In the ADNI AD group, 5 of 92 subjects fit the category "dementia unlikely due to AD" when at least one neuronal injury marker was negative. Conclusions: A large proportion of subjects with AD dementia in ADNI may be categorized more definitively as high-probability AD using the proposed biomarker scheme in the NIA-AA criteria. A minority of subjects may be excluded from the diagnosis of AD by using biomarkers in clinically categorized AD subjects. In a well-defined AD dementia population, significant biomarker inconsistency can be seen on a per-patient basis.

AB - Objective: Wedescribe the operationalization of theNational Institute on Aging-Alzheimer's Association (NIA-AA) workgroup diagnostic guidelines pertaining to Alzheimer disease (AD) dementia in a large multicenter group of subjects with AD dementia. Methods: Subjects with AD dementia from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with at least 1 amyloid biomarker (n = 211) were included in this report. Biomarker data from CSF Aβ42, amyloid PET, fluorodeoxyglucose-PET, and MRI were examined. The biomarker results were assessed on a per-patient basis and the subject categorization as defined in theNIA-AAworkgroup guidelines was determined. Results: When using a requirement that subjects have a positive amyloid biomarker and single neuronal injury marker having an AD pattern, 87% (48% for both neuronal injury biomarkers) of the subjects could be categorized as "high probability" for AD. Amyloid status of the combined Pittsburgh compound B-PET and CSF results showed an amyloid-negative rate of 10% in the AD group. In the ADNI AD group, 5 of 92 subjects fit the category "dementia unlikely due to AD" when at least one neuronal injury marker was negative. Conclusions: A large proportion of subjects with AD dementia in ADNI may be categorized more definitively as high-probability AD using the proposed biomarker scheme in the NIA-AA criteria. A minority of subjects may be excluded from the diagnosis of AD by using biomarkers in clinically categorized AD subjects. In a well-defined AD dementia population, significant biomarker inconsistency can be seen on a per-patient basis.

UR - http://www.scopus.com/inward/record.url?scp=84879072877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879072877&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e318295d6cf

DO - 10.1212/WNL.0b013e318295d6cf

M3 - Article

C2 - 23645596

AN - SCOPUS:84879072877

VL - 80

SP - 2130

EP - 2137

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 23

ER -